Intensity-modulated radiation therapy in early stage squamous cell carcinoma of the larynx: treatment trends and outcomes.

IMRT Laryngeal cancer Radiation therapy

Journal

Radiation oncology journal
ISSN: 2234-1900
Titre abrégé: Radiat Oncol J
Pays: Korea (South)
ID NLM: 101577577

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 06 12 2019
accepted: 17 01 2020
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 2 4 2020
Statut: ppublish

Résumé

Definitive radiotherapy remains a primary treatment option for early stage glottic cancer. Intensity-modulated radiation therapy (IMRT) has emerged as the standard treatment technique for advanced head and neck cancers, whereas three-dimensional conformal radiotherapy (3D-CRT) has remained standard for early glottic cancers. We used the National Cancer Database (NCDB) to identify predictors of IMRT use and effect on outcome in these patients. We queried the NCDB from 2004-2015 for squamous cell carcinoma of the glottic larynx staged Tis-T2N0 treated with radiation alone. Logistic regression was used to identify predictors of IMRT. Cox regression was used to identify factors predictive of overall survival. Propensity matching was conducted to account for indication bias. We identified 15,627 patients, of which 11% received IMRT. IMRT use rose from 2% in 2004 to 16% in 2015. Predictors of IMRT include: increased comorbidity, T2 stage, urban location, chemotherapy, treatment at an academic center, and later treatment year. Predictors of improved survival were female gender, higher income, lower stage, no chemotherapy, academic facility, and more remote year. There was no difference in survival between 3D-CRT and IMRT across all stages. The rate of IMRT use for early stage glottic laryngeal cancer has increased over time. There was no difference in outcome in patients receiving IMRT versus 3D-CRT across the cohort.

Identifiants

pubmed: 32229804
pii: roj.2019.00619
doi: 10.3857/roj.2019.00619
pmc: PMC7113149
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11-17

Références

Am J Otolaryngol. 1993 Mar-Apr;14(2):116-21
pubmed: 8484476
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1380-5
pubmed: 19942356
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87
pubmed: 10524409
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):337-43
pubmed: 26264629
Cancer. 2004 May 1;100(9):1786-92
pubmed: 15112257
Br J Radiol. 2012 May;85(1013):487-94
pubmed: 22556403
Stroke. 2011 Sep;42(9):2410-8
pubmed: 21817150
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82
pubmed: 16169681
Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):82-8
pubmed: 17413407
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
J Clin Oncol. 2006 Aug 1;24(22):3693-704
pubmed: 16832122
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Oral Oncol. 2015 Jul;51(7):716-23
pubmed: 25958831
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):461-6
pubmed: 20153124

Auteurs

Rodney E Wegner (RE)

Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

Stephen Abel (S)

Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

John J Bergin (JJ)

Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

Athanasios Colonias (A)

Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

Classifications MeSH